Andere talen Spero Therapeutics, Inc.

Aandelen

SPRO

US84833T1034

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,4 ^USD	-4,76%		-14,63%	-4,76%

13/03	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
13/03	Spero Therapeutics, Inc. rapporteert winstresultaten voor het vierde kwartaal eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	13/03
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update	13/03
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	06/03
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections	28/02
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference	26/02
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	09/02
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/01
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025	05/01
Spero Therapeutics Provides Corporate Update and 2024 Outlook	05/01
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	02/01
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	02/01
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M	13/11
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update	13/11
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	03/11
Spero Therapeutics to Present at Upcoming November Investor Conferences	01/11
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	01/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Spero Therapeutics, Inc.

Aandelen

SPRO

US84833T1034

Andere talen

Filters